McQueen F.,University of Auckland |
Elliott B.,Living Cell Technologies
Autoimmune diseases are characterised by lymphoproliferation in target tissues with B and T lymphocytes often arranged in pseudofollicles, mimicking the structure of peripheral lymph nodes. Target organ tissue damage produces the clinical phenotype which may be diverse ranging from autoimmune endocrinopathies to malabsorption (coeliac disease) to structural damage within bones and joints (rheumatoid arthritis). Recently, B cell depletion has been shown to be effective in many autoimmune conditions suggesting a common pathological origin for these conditions which might be triggered by an autoimmune B cell that has escaped deletion. We postulate that a mutation in a transcription factor early in B cell development might allow persistence and foster proliferation of a clone of autoimmune B cells, capable of producing autoantibodies. A similar common mutation within the JAK2 tyrosine kinase gene has recently been described associated with the myeloproliferative disorders which are also characterised by diverse clinical disease phenotypes. There is considerable evidence that autoimmune diseases could be indolent lymphoproliferative disorders of B-cell origin, extending the forbidden clone hypothesis first proposed in the 1950s. © 2010 Elsevier Ltd. Source
Pettingill L.N.,The Bionic Ear Institute |
Wise A.K.,The Bionic Ear Institute |
Wise A.K.,University of Melbourne |
Geaney M.S.,Living Cell Technologies |
And 2 more authors.
Exogenous neurotrophin delivery to the deaf cochlea can prevent deafness-induced auditory neuron degeneration, however, we have previously reported that these survival effects are rapidly lost if the treatment stops. In addition, there are concerns that current experimental techniques are not safe enough to be used clinically. Therefore, for such treatments to be clinically transferable, methods of neurotrophin treatment that are safe, biocompatible and can support long-term auditory neuron survival are necessary. Cell transplantation and gene transfer, combined with encapsulation technologies, have the potential to address these issues. This study investigated the survival-promoting effects of encapsulated BDNF over-expressing Schwann cells on auditory neurons in the deaf guinea pig. In comparison to control (empty) capsules, there was significantly greater auditory neuron survival following the cell-based BDNF treatment. Concurrent use of a cochlear implant is expected to result in even greater auditory neuron survival, and provide a clinically relevant method to support auditory neuron survival that may lead to improved speech perception and language outcomes for cochlear implant patients. © 2011 Pettingill et al. Source
Living Cell Technologies | Date: 2015-11-03
Pharmaceutical preparations and substances for the treatment of genetic, diabetic, metabolic, neurological, hepatological, ophthalmic, neurological, bone, and autoimmune diseases and conditions; cell preparations for the treatment of genetic, diabetic, metabolic, neurological, hepatological, ophthalmic, neurological, bone, and autoimmune diseases and conditions; living tissue in the nature of animal tissue from which cells can be harvested and used for medical purposes. Medical services; preparing cells for implanting into a human or other animal body; encapsulating cells for implanting into humans and animals; animal breeding services; consultancy and advisory services relating to the aforesaid services; providing information relating to the aforesaid services.
The Bionic Ear Institute and Living Cell Technologies | Date: 2013-12-17
The present invention is directed to the prevention or treatment of sensorineural hearing loss by administering a therapeutically effective amount of an implantable composition comprising encapsulated living choroid plexus cells.
Elliott R.B.,Living Cell Technologies
Current Opinion in Organ Transplantation
PURPOSE OF REVIEW: Porcine islet xenotransplantation into humans faces two major hurdles - safety issues related to xenosis and xenorejection of the transplants. The former has been overcome mainly by selection of a suitable disease-free source herd. RECENT FINDINGS: Four strategies have been employed to date to overcome the rejection, all of which have shown some efficacy in animal models. SUMMARY: Immune suppression, Sertoli cell co-transplantation and microencapsulation have been tried in type 1 diabetic humans with some clinical benefit derived reported from the latter two. Unaware hypoglycemia in particular seems amenable to the microencapsulation approach. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source